|Articles|November 10, 2021
Pharmacy Clinical Pearl of the Day: Ehlers-Danlos Syndrome
Author(s)Saro Arakelians, PharmD
Ehlers-Danlos syndrome typically causes overly flexible joints and stretchy, fragile skin.
Advertisement
Clinical Pearl of the Day: Ehlers-Danlos Syndrome
Ehlers-Danlos syndrome is a group of inherited disorders that affect your connective tissues—primarily your skin, joints, and blood vessel walls.
Insight:
- People who have Ehlers-Danlos syndrome usually have overly flexible joints and stretchy, fragile skin.
- This can become a problem if you have a wound that requires stitches, because the skin often isn't strong enough to hold them.
- A more severe form of the disorder, called vascular Ehlers-Danlos syndrome, can cause the walls of the blood vessels, intestines, or uterus to rupture.
- Symptoms may include overly flexible joints, stretchy skin, and fragile skin.
- People who have vascular Ehlers-Danlos syndrome often share distinctive facial features of a thin nose, thin upper lip, small earlobes, and prominent eyes.
- The cause of this disease could be genetics.
- Treatment options could include the use of various medications, such as pain medications to control any acute pain, as well as blood pressure medications to control the blood pressure and help keep the vessels healthy.
- Physical therapy and surgery may also be needed for advanced cases.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5